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Background: Acinic cell carcinoma (ACC) is a rare malignant epithelial neoplasm characterized by the presence of
malignant tubular acinar exocrine gland structures. Diagnosis is generally made in salivary glands and in the
pancreas. ACC of the breast has been reported in few cases only. Carriers of inherited mutations in the BRCA1 gene
are prone to the development of breast cancer, mainly invasive ductal or medullary type carcinomas. We describe
for the first time a BRCA1 mutation carrier with a diagnosis of ACC of the breast.
Case presentation: The patient developed an invasive ductal carcinoma (IDC) at the age of 40 years and an ACC
in the contralateral breast at 44 years. Immunohistochemical examination of the ACC revealed a triple negative
status (i.e., negativity for estrogen receptor, progesterone receptor and HER2 protein) and positivity for p53. Using a
combination of loss of heterozygosity (LOH) and sequencing analyses, the loss of the wild-type BRCA1 allele was
detected in both the ACC and the IDC. In addition, two different somatic TP53 mutations, one in the ACC only and
another one in the IDC only, were observed.
Conclusion: Both the immunohistochemical and molecular features observed in the ACC are typical of BRCA1-
associated breast cancers and suggest an involvement of the patient’s germline mutation in the disease. The
occurrence of rare histological types of breast cancers, including malignant phyllodes tumor, atypical medullary
carcinoma and metaplastic carcinoma, in BRCA1 mutation carriers has been already reported. Our findings further
broaden the spectrum of BRCA1-associated breast malignancies.
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Acinic cell carcinoma (ACC) is a rare histological type
of malignant epithelial neoplasm exhibiting acinic cell dif-
ferentiation. The typical locations are major and minor
salivary glands and pancreas, where it accounts for ap-
proximately 10% and 1% of all cancers, respectively [1-3].
ACC has been occasionally observed in other organs, in-
cluding lung, stomach, liver, retroperitoneum, lacrimal
glands and breast [4-19]. ACC of the breast was first
described by Roncaroli et al. in a 42-year-old woman who
complained of a palpable lump that had rapidly increased
in size and appeared at mammography as a well defined* Correspondence: paolo.radice@istitutotumori.mi.it
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distribution, and reproduction in any mediumlesion containing scattered granular calcifications [10].
Since then, a few additional cases have been reported in
patients aged between 23 and 80 years, including a male
subject [11-19]. Morphologically, ACC of the breast
resembles the homonymous salivary gland tumor due
to the formation of tubular acinar gland structures delim-
ited by a thin layer of connective tissue. Two distinct
patterns of growth have been described. The first is solid
or nesting, poorly circumscribed and infiltrating, often
accompanied by focal necrosis. The second pattern is
characterized by the formation of acinar, tubular, micro-
glandular and microcystic structures. The neoplastic cells
are polygonal or round, with an amphophilic cytoplasm
containing coarse brightly eosinophilic granules. The glan-
dular lumina contain an amorphous eosinophilic material
[20,21].
Approximately 10% of breast cancers show a her-
editary predisposition. It is estimated that nearly 20%tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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line mutations in either the BRCA1 or BRCA2 genes
[22,23]. BRCA1 mutation carriers face a lifetime risk
to develop breast cancer that ranges from 57% to 65%
[24,25]. The pathological features of breast tumors
arising in BRCA1 mutation carriers have been exten-
sively described. They are mostly high grade invasive
ductal not otherwise specified (NOS) or medullary
type carcinomas. High mitotic index, pushing mar-
gins, lymphocytic infiltration and areas of necrosis
are frequent findings. Immunoreactivity for estrogen
receptor (ER), progesterone receptor (PgR) and for
the human epidermal growth factor receptor 2
(HER2) is usually absent [26-28]. This profile, defined
as “triple negative” (TN), has been shown to be highly
predictive of the BRCA1 mutation carrier status [29].
BRCA1 is a tumor suppressor gene involved in the
control of cell cycle progression and of DNA double
strand break (DSB) repair. The vast majority of breast
tumors developing in BRCA1 carriers shows inactivation
of the wild-type allele by either somatic genetic (muta-
tions or loss of heterozygosity (LOH)) or epigenetic
(promoter hypermethylation) changes [30]. These occur-
rences lead to the absence of functional BRCA1 protein
and, thus, to genetic instability and tumor development.
In addition, breast tumors in BRCA1 mutation carriers
frequently show mutations of the TP53 gene and/or ab-
normal expression of the corresponding protein p53
[31,32].
In this study, we provide the first pathological, immu-
nohistochemical and molecular characterization of a
breast tumor of the ACC type developed in a BRCA1
mutation carrier.M
M M
Figure 1 Family tree of the patient (indicated by the arrow). Individua
(M) are indicated. No other family member could be tested for the presencCase presentation
Clinical course and pathological features
The patient is a 45-year-old woman with a familial his-
tory of breast and ovarian carcinomas and other cancers
(Figure 1). Her mother died at the age of 50 years from
ovarian cancer, and her maternal aunt developed breast
cancer at 64 years and ovarian cancer at 72 years. The
daughter of the latter patient died at 44 years from a
metastatic malignant tumor, consistent with a salivary
gland origin. Genetic testing of the patient’s maternal aunt
identified a constitutional BRCA1 mutation, c.4484 G>T,
causing the skipping of exon 14 [33,34]. Subsequently, the
presence of this mutation was ascertained in the subject of
this report at the age of 36 years, when still in good
health.
Following this finding, clinical examination and instru-
mental surveillance with mammography, magnetic res-
onance imaging (MRI) and ultrasonography were
initiated according to the institutional protocols for
BRCA gene mutation carriers. At the age of 40 years, a
poorly differentiated invasive ductal carcinoma (IDC),
measuring 25 mm in diameter, was diagnosed in the
upper outer quadrant of the right breast. The pathology
report described positive immunostaining for ER and
PgR and negativity for HER2. A radical mastectomy with
sentinel lymph node biopsy was performed. According
to the pathological TNM (tumor, node, metastasis) sta-
ging system, the tumor was pT2, pN0. The patient
received adjuvant chemotherapy with adriamycin, cyclo-
phosphamide, methotrexate and 5-fluorouracil, and hor-
monal therapy with tamoxifen and luteinizing-hormone-
releasing hormone (LH-RH) analogue. At the age of
41 years, two left axillary lymph nodes were biopsiedls affected with cancer, ages at diagnosis and BRCA1 mutation carriers
e of the mutation. BrCa, breast cancer; OvCa, ovarian cancer.
Figure 2 Haematoxylin and Eosin staining (A, B) and p53
immunostains (C) of ACC [x10 (A) and x40 (B, C) magnifications].
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tumor. One year later, the patient underwent prophylac-
tic salpingo-oophorectomy and the LH-RH analogue
was stopped, whereas the tamoxifen therapy was
switched to aromatase inhibitors.
At the age of 44 years, a breast MRI revealed a solid
mass with pushing margins in the upper outer quadrant
of the left breast. A mammary resection (lumpectomy)
was carried out, and the histological diagnosis was made
of ACC with a microglandular pattern of growth. On
gross examination, the tumor appeared as an ill-defined
yellowish firm area measuring 13 mm in its largest di-
mension. Microscopically, it was characterized by a dif-
fuse tightly packed proliferation of small acinar and
glandular structures, frequently intermixed with solid
nests of markedly eosinophilic larger cells. The acinar
and glandular structures were made of round cells with
a finely granular, weakly basophilic, or clear cytoplasm
resembling those of acinar cells of salivary glands. The
eosinophilic cells showed bright eosinophilic coarse
granules resembling those of intestinal Paneth cells
(Figure 2A,B).
Immunohistochemical stainings were performed using
the streptavidin-biotin peroxidase method, in accordance
with the manufacturer's instructions (Table 1). The neo-
plastic cells were immunohistochemically positive for
the S100 protein, epithelial membrane antigen (EMA),
p53 (Figure 2C) and alpha-1-antichymotrypsin (AACT)
whereas maspin, gross cystic disease fluid protein-15
(GCDFP), ER, PgR and HER2 were negative. Immunos-
tains for actin and calponin did not show myoepithelial
differentiation.
Two months later, a radical mastectomy was per-
formed. No residual tumor was found in the remaining
parenchymal tissue or in the two microscopically exam-
ined lymph nodes. The patient is alive and well
19 months after the surgery, with no evidence of disease
and still undergoing hormonal therapy.
A written consent approved by the Ethical Committee
of the Fondazione IRCCS Istituto Nazionale dei Tumori,
was obtained from the patient to the use of her bio-
logical samples for research purposes.
Genetic investigations
Formaldehyde-fixed, paraffin-embedded surgical speci-
mens of both the ACC and the IDC were retrieved and
reviewed by the pathologist. Tumor areas were manually
microdissected. DNA was extracted from tumor and
normal (peripheral blood leukocytes; PBLs) tissues using
commercial kits (QIAGEN). The region corresponding
to the BRCA1-associated D17S855 polymorphic micro-
satellite marker was amplified by polymerase chain reac-
tion (PCR) from the ACC and normal DNA, using a 50-
end fluorescent dye labeled forward primer (VWRInternational). The amplification products were sepa-
rated by capillary electrophoresis on an ABI 3130 Gen-
etic Analyzer (Applied Biosystems) and analyzed using
the Gene Mapper 4.0 software (Applied Biosystems).
The ratio between the peak area of the larger allele and
that of the smaller allele in tumor DNA (Figure 3B) was
calculated after normalization on the corresponding
ratio in the normal DNA (Figure 3A). LOH was assessed
in the tumor sample where a strong reduction (ca. 70%)
Table 1 Primary antibodies and dilutions used for the
immunohistochemical analyses and results
Antibody to Manufacturer Dilution Results
ER Ventana ready-to-use Negative
PgR Ventana ready-to-use Negative
HER2 Dako 1:1000 Negative
S100 protein Dako 1:2000 Positive
EMA Ventana ready-to-use Positive
GCDFP15 Signet 1:20 Negative
P53 Novocastra 1:200 Positive
AACT Dako 1:1000 Positive
Actin Dako 1:400 Negative
Maspin Pharmingen 1:500 Negative
Calponin BioGenex 1:400 Negative
ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal
growth factor receptor 2; EMA, epithelial membrane antigen; GCDFP15, gross
cystic disease fluid protein-15; AACT, alpha-1-antichymotrypsin.
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DNA. To evaluate which BRCA1 allele was lost, we per-
formed the sequence analysis of the genomic region
encompassing the BRCA1 constitutional mutation in
normal and ACC DNA. The sequence reactions were
performed with the ABI PRISMW Big Dye Terminator
Cycle Sequencing Kit (Applied Biosystems), run on an
ABI 3130 Genetic Analyzer and examined using the Se-
quencing Analysis Software (Applied Biosystems). A
strong reduction of the constitutionally wild-type allele
(G) was observed in the ACC (Figure 3E), compared to
normal DNA (Figure 3D). Therefore, the ACC presented











































Figure 3 Assessment of the loss of the wild-type BRCA1 allele in tumo
the peripheral blood leukocytes (PBLs) DNA of the patient are indicated. A
observed in both the ACC and the IDC DNA (indicated by the arrows). D-F
mutation is indicated by the arrows. A reduction of the wild-type G allele iconstitutional mutation coupled with the somatic loss of
the wild-type allele.
The sequencing of coding exons (2 to 11) of the TP53
gene in the ACC identified the c.654_655insGTG muta-
tion (Figure 4B), which was not present in the normal
DNA (Figure 4A). This mutation was previously
described in a case of Burkitt lymphoma [35].
Using the above described approaches, loss of the
wild-type BRCA1 allele (Figures 3C, 3F) and a TP53 mu-
tation (c.994-1 G>A) (Figure 4F) were also observed in
the IDC sample. The TP53 mutation was not present in
both the normal (Figure 4D) and the ACC (Figure 4E)
DNA. Conversely, the TP53 mutation observed in the
ACC was absent in the IDC (Figure 4C).
Discussion
A few studies have recently documented the occurrence
of ACCs in patients with hereditary susceptibility to can-
cer. Five reports have been published describing the de-
velopment of ACCs of the pancreas in subjects carrying
germline mutations in genes predisposing to breast and
colon cancers. More specifically, a pancreatic ACC was
reported in a BRCA1 male mutation carrier with a fam-
ily history positive for early-onset breast cancers. The
proband had a previous history of papillary renal and
colon cancers and was affected with acromegaly [36].
Skoulidis et al. described ACCs of the pancreas in three
subjects with BRCA2 germline mutations and detected
LOH at the BRCA2 locus in the tumors [37]. Further-
more, the diagnosis of pancreatic ACC was made in a
46-year-old male affected with liposarcoma, polyps and
hamartomas of the colon, who carried a germlineIDCCC
C
F
r DNA. A-C) The two D17S855 alleles (al_147 and al_155) present in
strong reduction of the peak corresponding to the al_155 allele is
) BRCA1 sequence analysis. The site of the germline c.4484 G>T
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Figure 4 TP53 sequence analysis. A-C) DNA sequences showing the presence of the c.654_655insGTG mutation in the ACC and its absence in
the IDC and PBL DNA. D-F) DNA sequences showing the presence of the c.994 -1 G>A mutation in the ICD and its absence in the ACC and PBL
DNA. The position of the mutations is indicated by the arrows. PBLs, peripheral blood leukocytes.
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Jeghers syndrome. By LOH analysis, the authors assessed
a link between the loss of the wild-type STK11/LKB1 al-
lele and the onset of the ACC [38]. Interestingly, no
STK11/LKB1 mutation or altered RNA expression were,
by contrast, found in five sporadic ACCs of the pancreas
[39]. A metastatic ACC of the pancreas was described in
a female patient carrying a mutation in MSH6, one of
the genes responsible for the Lynch syndrome. The pa-
tient had received previous diagnoses of invasive breast
cancer, and sebaceous and basal cell carcinomas of the
skin [40]. Finally, germline mutations of PRKAR1A, the
gene responsible for the Carney complex, were observed
in two patients with pancreatic ACCs. LOH at the gene
locus and absence of the corresponding protein expres-
sion were observed in tumor cells [41].
An ACC of the retromolar trigone region was
described in a 35-year-old patient with a clinical diagno-
sis of Cowden disease and a genetic analysis positive for
a pathogenic mutation in PTEN [42]. Cowden disease is
characterized by the presence of multiple hamartomas, atype of malformation mainly affecting the gastrointes-
tinal tract, and an increased susceptibility to breast, thy-
roid and endometrial cancers [43].
To the best of our knowledge, our report is the first de-
scribing a primary ACC of the mammary gland in a
BRCA1 mutation carrier. Histologically, the tumor dis-
played two populations, one characterized by a micro-
glandular pattern of growth and the other consisting of
solid nests of cells. The glandular cells were characterized
by basophilic cytoplasm, while the latter showed eosino-
philic cytoplasmic granules. The results of immunohisto-
chemical analysis were in accordance with previous
reports and confirmed the diagnosis of ACC [11-19]. In
addition, the tumor exhibited a TN phenotype, in agree-
ment with four out of the five previous reports of ACCs of
the breast for which the results of ER, PgR and HER2
stains were available [13,15,17-19].
Molecular characterization detected the loss of the
BRCA1 wild-type allele and a TP53 somatic mutation in
tumor DNA. The involvement of TP53 in tumor develop-
ment was confirmed by immunohistochemistry that showed
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ACC of the breast that had been examined for p53 expres-
sion tested negative on immunostaining [13]. We also inves-
tigated for LOH at BRCA1 locus and for TP53 mutations
the DNA extracted from the IDC that the patient had devel-
oped few years before the diagnosis of ACC. Like the ACC,
the IDC displayed loss of the BRCA1 wild type allele and
the somatic TP53mutation. However, this mutation was dif-
ferent from the one detected in the ACC, indicating a di-
verse origin of the two tumors. Our results are consistent
with the observation that somatic alterations of BRCA1 and
TP53 are frequent in breast cancers, particularly those of the
TN phenotype [44,45]. Both genes are key players in the
control of DNA damage response and their impairment
leads to tumor development by inducing, among other
mechanisms, genomic instability.
Our findings are consistent with previous studies
reporting LOH at BRCA1 locus and TP53 abnormalities
as frequent events in breast cancers occurring in BRCA1
mutation carriers [31,32]. Therefore, we may argue a
causal role of the genetic background of the patient,
which made her prone to breast cancer, not only in the
development of the IDC, but also in the rare phenotypic
expression of the ACC. Interestingly, a considerable pro-
portion (7/14 = 50%) of the previously documented
cases of ACC of the breast were of early-onset (age at
diagnosis <50 years) [10-12,14-16,18]. This observation
suggests the involvement of hereditary factors in at least
a fraction of these patients.
Atypical and unusual histologic features of breast can-
cers in BRCA1 mutation carriers have been reported.
A malignant phyllodes tumor was observed in a 43-
years-old patient, who tested positive for the c.5095C>T
(p.R1699W) missense pathogenic mutation [34,46]. In
addition, Ashida et al. reported an atypical medullary
carcinoma of the breast with cartilaginous metaplasia in
a young patient with a nonsense mutation in exon 5
[47]. The association of BRCA1 mutations with other
histotypes, commonly grouped under the term of meta-
plastic breast carcinomas (MBC) and including squa-
mous, adenosquamous and tumors with biphasic
morphology carcinomas (so-called carcinosarcomas),
was also described. Breuer et al. reported on a young
woman, carrying the c.181 T>G (p.C61G) mutation, who
had developed bilateral asynchronous squamous breast
cancers at 25 and at 28 years of age [48]. Suspitsin et al.
described a mixed epithelial/mesenchimal metaplastic
carcinoma that was diagnosed in a 35-year-old female
carrier of the c.5266dupC mutation. The molecular ana-
lysis revealed the loss of the wild-type BRCA1 allele in
both the epithelial and the mesenchymal components of
the tumor, supporting the role of BRCA1 in its develop-
ment [49]. A low-grade adenosquamous carcinoma of
the breast described by Noel et al. was diagnosed in a49-year-old woman with a previous diagnosis of IDC
and the presence of the c.66dupA mutation [50]. Finally,
Rashid et al. reported a biphasic carcinoma composed of
sarcomatous and malignant epithelial components in a
22-year-old proband who carried the c.68_69delAG mu-
tation [51]. With the single exception of the study of
Suspitsin et al., the above mentioned reports described a
“basal like” phenotype of the tumor tissues, on the basis
of the TN status and the positivity by immunohysto-
chemistry of the basal cytokeratin CK5/6. In fact, the
majority of BRCA1-related breast cancers express basal
cytokeratins [27] and the discovery of this status in the
MBCs reported to date is in favor of the involvement of
BRCA1 in the tumor development.
Conclusions
We described the first case of a BRCA1 mutation carrier
affected with an ACC of the breast, a very rare histo-
logical subtype of mammary tumor. Immunohistochem-
ical analyses and molecular investigations of the ACC
provided evidences suggestive of an involvement of the
constitutional BRCA1 mutation in the pathogenesis of
disease. In addition to the present case, studies reporting
on malignant phyllodes tumor, atypical medullary car-
cinoma and MBCs of the breast support the notion that
rare histological types of breast cancers can occur in
patients with mutations in BRCA1 and that their devel-
opment is mediated by the presence of such mutations.
Further studies are needed to understand which add-
itional factors contribute to make BRCA1 mutation car-
riers prone to the expression of different breast tumor
phenotypes.
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